Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

@article{Santoro2008PemetrexedPC,
  title={Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemona{\"i}ve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program},
  author={Armando Santoro and M. O'Brien and Rolf Stahel and Kris Nackaerts and Paul Baas and Meinolf Karthaus and Wilfried Eberhardt and Luis Paz-Ares and Stein Harald Sundstr{\o}m and Yushan Liu and Veronique Ripoche and Johannes Blatter and Carla M Visseren-Grul and Christian Manegold},
  journal={Journal of Thoracic Oncology},
  year={2008},
  volume={3},
  pages={756-763}
}
Introduction: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pemetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pemetrexed in combination with cisplatin or… 
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
TLDR
While this randomized phase II trial met its primary endpoint of PFS at 4 months, other parameters such as response rate and overall survival suggest that the addition of CBP501 does not improve the efficacy of standard chemotherapy for MPM.
Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience
TLDR
Though the data reflect a small sample size, pemetrexed plus cisplatin accomplished a particularly high clinical benefit rate on chemo-naïve patients.
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
TLDR
This study confirmed the activity of the carboplatin/ pemetrexed combination in the first-line treatment of patients with MPM, and it is a viable option, especially in cases in which side effects are generally anticipated.
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
TLDR
PEM with or without a platinum agent was both active and well tolerated in patients with peritoneal mesothelioma.
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
TLDR
Maintenance pemetrexed following initial pemberrexed and platinum chemotherapy does not improve progression-free survival (PFS) in patients with MPM.
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
TLDR
Assessment of the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma concluded that further data are needed before drawing any definite conclusion on the role of bevacsumab in MPM.
Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.
TLDR
Treatment with pemetrexed was generally well tolerated and showed safety and effectiveness comparable to prior clinical trials, and appeared to have enrolled a major portion of Japanese MPM patients.
Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
TLDR
Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy and efficacy outcomes were better for chemonaïve than for pretreated patients, and P was less hematotoxic than PC or PCb.
Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial
TLDR
Ganetespib can be combined safely with pemetrexed and platinum chemotherapy to treat patients with MPM and this class of agent should be investigated in larger randomized studies.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
TLDR
Nivolumab plus ipilimumab provided significant and clinically meaningful improvements in overall survival versus standard-of-care chemotherapy, supporting the use of this first-in-class regimen that has been approved in the USA as of October, 2020, for previously untreated unresectable MPM.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
TLDR
In this large cohort, 67.7% of patients treated with first-line chemotherapy experienced a response or stable disease and survival time and toxicity from this EAP were promising for this difficult-to-treat disease.
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
TLDR
Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma.
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
TLDR
It is confirmed that a combination of cis platin and an antifolate is superior to cisplatin alone in patients with MPM, without harmful effect on HRQOL.
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
  • G. Ceresoli, P. Zucali, +10 authors A. Santoro
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Disease control rate, time to disease progression, and overall survival were similar to the results achieved with the standard regimen of pemetrexed and cisplatin, suggesting that the carboplatin combination could be an alternative option for these patients.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
  • A. Hughes, P. Calvert, +8 authors H. Calvert
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
The maximum tolerated dose (MTD) of pemetrexed and carboplatin given in combination is both active and well tolerated in MPM and deserves further exploration.
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
  • A. Chahinian, K. Antman, +7 authors L. Leone
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
In this randomized phase II trial, the overall response rates, time to treatment failure, and overall survival appear to be similar for the two regimens tested.
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
TLDR
Frequently administered cisplatin in combination with oral etoposide has a moderate but definite activity in pleural mesothelioma.
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study
TLDR
The combination of doxorubicin and cisplatin is effective and well tolerated and might be considered for palliation of symptomatic patients with DMPM.
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
TLDR
It is concluded that for this small group of patients, the combination cisplatin-vinblastine is effective, with acceptable toxicity in malignant mesothelioma, and further study with a larger number of patients is necessary.
FDA drug approval summaries: pemetrexed (Alimta).
The purpose of this report is to summarize information on pemetrexed (LY231514; MTA; Alimta; Eli Lilly and Company; Indianapolis, IN), a drug recently approved by the U.S. Food and Drug
...
1
2
3
4
...